NASDAQ:TCDATricida Stock Price, Forecast & News

Tricida's stock was trading at $28.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TCDA stock has decreased by 7.3% and is now trading at $26.00. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Tricida.

Tricida is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Tricida.

Tricida Inc (NASDAQ:TCDA) posted its earnings results on Thursday, May, 7th. The company reported ($1.49) earnings per share for the quarter, missing analysts' consensus estimates of ($1.41) by $0.08. View Tricida's earnings history.

2 analysts have issued 1 year price objectives for Tricida's stock. Their forecasts range from $50.00 to $50.00. On average, they expect Tricida's share price to reach $50.00 in the next year. This suggests a possible upside of 92.3% from the stock's current price. View analysts' price targets for Tricida.

News headlines about TCDA stock have trended somewhat positive on Sunday, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Tricida earned a daily sentiment score of 1.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about Tricida.

Tricida saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 4,740,000 shares, an increase of 5.3% from the June 15th total of 4,500,000 shares. Based on an average daily volume of 334,200 shares, the short-interest ratio is presently 14.2 days. Currently, 12.3% of the company's stock are sold short. View Tricida's Current Options Chain.

Some companies that are related to Tricida include United Therapeutics (UTHR), Ultragenyx Pharmaceutical (RARE), Reata Pharmaceuticals (RETA), Zai Lab (ZLAB), Mirati Therapeutics (MRTX), Legend Biotech (LEGN), Emergent Biosolutions (EBS), Arrowhead Pharmaceuticals (ARWR), Biohaven Pharmaceutical (BHVN), Myokardia (MYOK), Global Blood Therapeutics (GBT), Blueprint Medicines (BPMC), Nektar Therapeutics (NKTR), Evotec (EVTCY) and Amicus Therapeutics (FOLD). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tricida investors own include Gilead Sciences (GILD), Madrigal Pharmaceuticals (MDGL), Myovant Sciences (MYOV), Arena Pharmaceuticals (ARNA), Atara Biotherapeutics (ATRA), Biohaven Pharmaceutical (BHVN), Crispr Therapeutics (CRSP), CytomX Therapeutics (CTMX), Exelixis (EXEL) and Amicus Therapeutics (FOLD).

(TCDA) raised $175 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 10,300,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen served as the underwriters for the IPO.

Tricida trades on the NASDAQ under the ticker symbol "TCDA."

Shares of TCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TCDA stock can currently be purchased for approximately $26.00.

Tricida has a market capitalization of $1.30 billion. The company earns $-176,810,000.00 in net income (profit) each year or ($3.72) on an earnings per share basis. Tricida employs 76 workers across the globe.

The official website for Tricida is www.tricida.com.

Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-429-7800 or via email at [email protected]